Trial watch: intratumoral immunotherapy

While chemotherapy and radiotherapy remain the first-line approaches for the management of most unresectable tumors, immunotherapy has emerged in the past two decades as a game-changing treatment, notably with the clinical success of immune checkpoint inhibitors. Immunotherapies aim at (re)activatin...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Juliette Humeau, Julie Le Naour, Lorenzo Galluzzi, Guido Kroemer, Jonathan G. Pol
Formato:	article
Lenguaje:	EN
Publicado:	Taylor & Francis Group 2021
Materias:	antitumor immunity cancer immunosurveillance immunotherapy intralesional injection in situ vaccination Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/860d117f4d7c441c9071fddcbf85143f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:860d117f4d7c441c9071fddcbf85143f
record_format	dspace
spelling	oai:doaj.org-article:860d117f4d7c441c9071fddcbf85143f2021-11-04T15:00:45ZTrial watch: intratumoral immunotherapy2162-402X10.1080/2162402X.2021.1984677https://doaj.org/article/860d117f4d7c441c9071fddcbf85143f2021-01-01T00:00:00Zhttp://dx.doi.org/10.1080/2162402X.2021.1984677https://doaj.org/toc/2162-402XWhile chemotherapy and radiotherapy remain the first-line approaches for the management of most unresectable tumors, immunotherapy has emerged in the past two decades as a game-changing treatment, notably with the clinical success of immune checkpoint inhibitors. Immunotherapies aim at (re)activating anticancer immune responses which occur in two main steps: (1) the activation and expansion of tumor-specific T cells following cross-presentation of tumor antigens by specialized myeloid cells (priming phase); and (2) the immunological clearance of malignant cells by these antitumor T lymphocytes (effector phase). Therapeutic vaccines, adjuvants, monoclonal antibodies, cytokines, immunogenic cell death-inducing agents including oncolytic viruses, anthracycline-based chemotherapy and radiotherapy, as well as adoptive cell transfer, all act at different levels of this cascade to (re)instate cancer immunosurveillance. Intratumoral delivery of these immunotherapeutics is being tested in clinical trials to promote superior antitumor immune activity in the context of limited systemic toxicity.Juliette HumeauJulie Le NaourLorenzo GalluzziGuido KroemerJonathan G. PolTaylor & Francis Grouparticleantitumor immunitycancer immunosurveillanceimmunotherapyintralesional injectionin situ vaccinationImmunologic diseases. AllergyRC581-607Neoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENOncoImmunology, Vol 10, Iss 1 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	antitumor immunity cancer immunosurveillance immunotherapy intralesional injection in situ vaccination Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	antitumor immunity cancer immunosurveillance immunotherapy intralesional injection in situ vaccination Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Juliette Humeau Julie Le Naour Lorenzo Galluzzi Guido Kroemer Jonathan G. Pol Trial watch: intratumoral immunotherapy
description	While chemotherapy and radiotherapy remain the first-line approaches for the management of most unresectable tumors, immunotherapy has emerged in the past two decades as a game-changing treatment, notably with the clinical success of immune checkpoint inhibitors. Immunotherapies aim at (re)activating anticancer immune responses which occur in two main steps: (1) the activation and expansion of tumor-specific T cells following cross-presentation of tumor antigens by specialized myeloid cells (priming phase); and (2) the immunological clearance of malignant cells by these antitumor T lymphocytes (effector phase). Therapeutic vaccines, adjuvants, monoclonal antibodies, cytokines, immunogenic cell death-inducing agents including oncolytic viruses, anthracycline-based chemotherapy and radiotherapy, as well as adoptive cell transfer, all act at different levels of this cascade to (re)instate cancer immunosurveillance. Intratumoral delivery of these immunotherapeutics is being tested in clinical trials to promote superior antitumor immune activity in the context of limited systemic toxicity.
format	article
author	Juliette Humeau Julie Le Naour Lorenzo Galluzzi Guido Kroemer Jonathan G. Pol
author_facet	Juliette Humeau Julie Le Naour Lorenzo Galluzzi Guido Kroemer Jonathan G. Pol
author_sort	Juliette Humeau
title	Trial watch: intratumoral immunotherapy
title_short	Trial watch: intratumoral immunotherapy
title_full	Trial watch: intratumoral immunotherapy
title_fullStr	Trial watch: intratumoral immunotherapy
title_full_unstemmed	Trial watch: intratumoral immunotherapy
title_sort	trial watch: intratumoral immunotherapy
publisher	Taylor & Francis Group
publishDate	2021
url	https://doaj.org/article/860d117f4d7c441c9071fddcbf85143f
work_keys_str_mv	AT juliettehumeau trialwatchintratumoralimmunotherapy AT julielenaour trialwatchintratumoralimmunotherapy AT lorenzogalluzzi trialwatchintratumoralimmunotherapy AT guidokroemer trialwatchintratumoralimmunotherapy AT jonathangpol trialwatchintratumoralimmunotherapy
_version_	1718444782736375808

Trial watch: intratumoral immunotherapy

Ejemplares similares